DE202008006598U1 - Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung - Google Patents

Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung Download PDF

Info

Publication number
DE202008006598U1
DE202008006598U1 DE202008006598U DE202008006598U DE202008006598U1 DE 202008006598 U1 DE202008006598 U1 DE 202008006598U1 DE 202008006598 U DE202008006598 U DE 202008006598U DE 202008006598 U DE202008006598 U DE 202008006598U DE 202008006598 U1 DE202008006598 U1 DE 202008006598U1
Authority
DE
Germany
Prior art keywords
allergen
dosage form
administration
allergy
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202008006598U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALK Abello AS
Original Assignee
ALK Abello AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE202008006598(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALK Abello AS filed Critical ALK Abello AS
Publication of DE202008006598U1 publication Critical patent/DE202008006598U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE202008006598U 2008-04-11 2008-05-15 Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung Expired - Lifetime DE202008006598U1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK200800533 2008-04-11
DKPA200800533 2008-04-11

Publications (1)

Publication Number Publication Date
DE202008006598U1 true DE202008006598U1 (de) 2008-10-02

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202008006598U Expired - Lifetime DE202008006598U1 (de) 2008-04-11 2008-05-15 Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Country Status (12)

Country Link
US (2) US9248097B2 (https=)
EP (1) EP2265285B1 (https=)
JP (2) JP5618981B2 (https=)
CN (1) CN102014954A (https=)
AU (1) AU2009235490B2 (https=)
BR (1) BRPI0911433A2 (https=)
CA (1) CA2720455A1 (https=)
DE (1) DE202008006598U1 (https=)
EA (1) EA019202B1 (https=)
ES (1) ES2406391T3 (https=)
MX (1) MX2010011012A (https=)
WO (1) WO2009124954A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005528A (es) * 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
KR20130118884A (ko) 2010-10-15 2013-10-30 알크-아벨로 에이/에스 알레르겐 소스 물질로부터 유도된 무관련 알레르겐을 이용한 과민성 면역반응의 억제
US20120100163A1 (en) * 2010-10-15 2012-04-26 Alk-Abello A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
WO2012148549A1 (en) 2011-02-25 2012-11-01 Benaroya Research Institute Detection of an immune response
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
SG11201402650RA (en) 2012-01-16 2014-06-27 Elizabeth Mckenna Compositions and methods for the treatment of hepatic diseases and disorders
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
BR112015006264A2 (pt) 2012-09-21 2017-07-04 Mckenna Elizabeth composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR102695088B1 (ko) 2014-02-28 2024-08-16 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
WO2021011614A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP7836754B2 (ja) 2019-08-05 2026-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
EP4513185A1 (en) * 2023-08-22 2025-02-26 Luxembourg Institute of Health (LIH) Early response biomarkers for allergen immunotherapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047680A1 (en) 1998-03-16 1999-09-23 Alk-Abelló A/S Mutant recombinant allergens
WO2002040676A2 (en) 2000-11-16 2002-05-23 Alk-Abelló A/S Mutant allergens
WO2003096869A2 (en) 2002-05-16 2003-11-27 Alk Abelló A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
WO2004047794A2 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S An allergen dosage form
WO2007038926A1 (en) 2005-10-04 2007-04-12 Alk-Abelló A/S Solid vaccine formulation
WO2007051476A1 (en) 2005-11-04 2007-05-10 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
US8491909B2 (en) 2004-02-06 2013-07-23 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
JP2007524096A (ja) 2004-02-26 2007-08-23 アルカベロ アクチェセルスカプ 粘膜投与用ワクチンの治療可能性の評価方法
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
WO2006050729A2 (en) 2004-11-10 2006-05-18 Alk-Abellò A/S Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
PT1812059E (pt) * 2004-11-10 2010-07-26 Alk Abelle As MéTODO DE TRATAMENTO PREVENTIVO DA ALERGIA POR ADMINISTRAÆO POR VIA MUCOSAL DE UMA VACINA PARA A ALERGIA
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用变态反应疫苗预防性治疗变态反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
EP1974746B1 (en) * 2007-03-28 2012-01-11 Alk-Abelló A/S Use of an adjuvanted allergy vaccine formulation for parenteral administration
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047680A1 (en) 1998-03-16 1999-09-23 Alk-Abelló A/S Mutant recombinant allergens
WO2002040676A2 (en) 2000-11-16 2002-05-23 Alk-Abelló A/S Mutant allergens
WO2003096869A2 (en) 2002-05-16 2003-11-27 Alk Abelló A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
WO2004047794A2 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S An allergen dosage form
WO2007038926A1 (en) 2005-10-04 2007-04-12 Alk-Abelló A/S Solid vaccine formulation
WO2007051476A1 (en) 2005-11-04 2007-05-10 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Allergenic extracts", H. Ipsen et al., Kapitel 20 in Allergy, principle and practise (Herausg. S. Manning) 1993
"Methods of the allergen products testing Laboratory" "ELISA competition assay". Seite 15, #49N-0012, FDA, Oktober 1993
Haugaard et al., J. Allergy Clin Immunol, Bd. 91, Nr. 3, S. 709-722, März 1993
Mosby-Year Book, St. Louis und Löwenstein H. (1980) Arb Paul Ehrlich Inst 75:122
P. M. Callahan et al., Pharmaceutical Research Bd. 8, Nr. 7,851-858 (1991) und Vaccine Design. The Subunit and Adjuvant Approach
Seidenberg et al. (Clinical and Experimental Allergy, 36, 1201-1212, British Society for Allergy and Clinical Immunology, Annual Conference - Juli 2006, Abstract S17)
The Handbook of Chemistry and Physics 56. Ausg., Abschnitt B, Kapitel 7 (197576)

Also Published As

Publication number Publication date
BRPI0911433A2 (pt) 2016-07-26
CN102014954A (zh) 2011-04-13
US20110142934A1 (en) 2011-06-16
EP2265285B1 (en) 2013-03-20
JP5618981B2 (ja) 2014-11-05
WO2009124954A1 (en) 2009-10-15
HK1147946A1 (en) 2011-08-26
CA2720455A1 (en) 2009-10-15
AU2009235490A1 (en) 2009-10-15
EP2265285A1 (en) 2010-12-29
AU2009235490B2 (en) 2013-10-24
MX2010011012A (es) 2010-11-12
US20140127298A1 (en) 2014-05-08
EA019202B1 (ru) 2014-01-30
JP2011516521A (ja) 2011-05-26
JP2015013891A (ja) 2015-01-22
EA201071182A1 (ru) 2011-06-30
US9248097B2 (en) 2016-02-02
ES2406391T3 (es) 2013-06-06

Similar Documents

Publication Publication Date Title
DE202008006598U1 (de) Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
DE60032250T2 (de) Behandlung von Allergien
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
Ebner et al. Booster immunotherapy (BIT)
DE202007004567U1 (de) Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
AU2008231722B2 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
KR20070057963A (ko) 구강 점막 투여용 액상 알레르기 백신 제형
US20120141536A1 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
CN101340892A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
CN103933562A (zh) 用于口腔粘膜给药的液体变态反应性疫苗制剂的用途
HK1110773B (en) Use of a liquid allergy vaccine formulation for oromucosal administration
HK1124790B (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration
HK1147946B (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
ZA200702413B (en) Liquid allergy vaccine formulation for oromucosal administration
HK1087008A1 (zh) 过敏原剂型
HK1087008B (en) An allergen dosage form
HK1106447B (en) Liquid allergy vaccine formulation for oromucosal administration

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20081106

R150 Utility model maintained after payment of first maintenance fee after three years
R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20111025

R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20140522

R152 Utility model maintained after payment of third maintenance fee after eight years
R071 Expiry of right